NO20093592L - Medikament for behandling av diabetes - Google Patents

Medikament for behandling av diabetes

Info

Publication number
NO20093592L
NO20093592L NO20093592A NO20093592A NO20093592L NO 20093592 L NO20093592 L NO 20093592L NO 20093592 A NO20093592 A NO 20093592A NO 20093592 A NO20093592 A NO 20093592A NO 20093592 L NO20093592 L NO 20093592L
Authority
NO
Norway
Prior art keywords
medication
diabetes
treatment
diabetic
patients
Prior art date
Application number
NO20093592A
Other languages
English (en)
Norwegian (no)
Inventor
Andrew A Wolff
Marcus Jerling
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20093592L publication Critical patent/NO20093592L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20093592A 2007-05-31 2009-12-23 Medikament for behandling av diabetes NO20093592L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/070140 WO2008147417A1 (en) 2007-05-31 2007-05-31 Method of treating diabetes

Publications (1)

Publication Number Publication Date
NO20093592L true NO20093592L (no) 2010-01-20

Family

ID=38812044

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20093592A NO20093592L (no) 2007-05-31 2009-12-23 Medikament for behandling av diabetes

Country Status (11)

Country Link
EP (1) EP2152268A1 (ko)
JP (1) JP2010528112A (ko)
KR (1) KR20100038322A (ko)
CN (1) CN101678017A (ko)
AU (1) AU2007354300A1 (ko)
BR (1) BRPI0721741A2 (ko)
CA (1) CA2687381A1 (ko)
IL (1) IL202002A0 (ko)
MX (1) MX2009012957A (ko)
NO (1) NO20093592L (ko)
WO (1) WO2008147417A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US20040063717A1 (en) 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
RU2691620C1 (ru) * 2018-11-26 2019-06-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования риска развития ишемической болезни сердца у пациентов с сахарным диабетом 2 типа в сочетании с субклиническим тиреотоксикозом
CN110812344A (zh) * 2019-12-17 2020-02-21 卓和药业集团有限公司 一种治疗糖尿病合并心绞痛的药物组合物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
BRPI0606403A2 (pt) * 2005-01-06 2009-06-23 Cv Therapeutics Inc formulações farmacêuticas com liberação sustentada e seus usos

Also Published As

Publication number Publication date
IL202002A0 (en) 2010-06-16
BRPI0721741A2 (pt) 2013-02-13
MX2009012957A (es) 2010-03-03
KR20100038322A (ko) 2010-04-14
WO2008147417A1 (en) 2008-12-04
EP2152268A1 (en) 2010-02-17
JP2010528112A (ja) 2010-08-19
CA2687381A1 (en) 2008-12-04
AU2007354300A1 (en) 2008-12-04
CN101678017A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
Zhernakova et al. Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome
Graff et al. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment
Gradman et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study
Gallego et al. Safety and tolerability of antipsychotic polypharmacy
WO2010049678A3 (en) Treatment of energy utilization diseases
Howes et al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance
HK1136943A1 (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2010008739A3 (en) Aryl gpr119 agonists and uses thereof
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
NO20093592L (no) Medikament for behandling av diabetes
Zhang et al. Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial
ATE516300T1 (de) Neuromedin-u-rezeptoragonisten und ihre verwendung
AU2008317057A8 (en) Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
WO2007024555A3 (en) Electronic personal health record system
WO2006105440A3 (en) Nicotinamide riboside and analogues thereof
WO2009057119A3 (en) Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
WO2008108958A3 (en) Benzimidazole derivatives and methods of use thereof
TNSN05065A1 (en) Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes
McCallum et al. Longitudinal blood pressure control, long-term mortality, and predictive utility of serum liver enzymes and bilirubin in hypertensive patients
Zhang et al. Amoxicillin/clavulanic acid‐warfarin drug interaction: a randomized controlled trial
WO2008070168A8 (en) Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
TW200833688A (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
Davies et al. An inherited variant in the gene coding for vitamin D‐binding protein and survival from cutaneous melanoma: a B io G eno MEL study
Kreutz et al. Cytochrome P450 3A4* 22, PPAR-α, and ARNT polymorphisms and clopidogrel response

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application